Roche has appointed Dan Malarek as President and CEO of Roche Diagnostics North America, effective August 1, 2026. The leadership transition follows the planned retirement of Brad Moore and includes the appointment of Antonio Vergara to a newly created U.S. commercial leadership position.
Key Takeaways
- Roche appointed Dan Malarek as President and CEO of Roche Diagnostics North America.
- Malarek succeeds Brad Moore, who will retire at the end of July 2026.
- The leadership change takes effect on August 1, 2026.
- Antonio Vergara will become Chief Commercial Officer of Roche Diagnostics U.S.
- Vera Grossmann will serve as interim CEO of Foundation Medicine during the search for a permanent successor.
Roche Diagnostics North America CEO Dan Malarek will assume leadership of the company’s North American diagnostics business on August 1, 2026, following Roche’s announcement of a broader executive transition affecting its regional commercial organization and Foundation Medicine. The appointments establish new leadership for several key positions while marking the retirement of Brad Moore.
The company confirmed that Malarek will become President and CEO of Roche Diagnostics North America, succeeding Moore after his retirement at the end of July. The role remains based at Roche Diagnostics’ North America headquarters in Indianapolis and reports to Matt Sause, Global CEO of Roche Diagnostics.
Roche Confirms Dan Malarek as North America CEO
The appointment places Malarek in charge of Roche Diagnostics North America beginning August 1, 2026. He currently serves as Chief Executive Officer of Foundation Medicine Inc., an independent affiliate within the Roche Group.
The leadership transition reflects principles commonly seen in CEO succession planning, with Roche announcing a structured handover before the effective date.
According to Roche, the leadership transition includes responsibilities for overseeing the company’s diagnostics operations across North America. Malarek will report directly to Matt Sause in his new position.
The announcement also confirmed that Brad Moore will retire after nearly a decade with Roche. Moore has led Roche Diagnostics North America and will conclude his tenure at the end of July before Malarek assumes the role.
The transition represents a planned executive succession announced by the company, with appointments taking effect on the same date to maintain continuity across multiple business units.
Leadership Transition Follows Brad Moore’s Retirement
Brad Moore’s retirement concludes a leadership period spanning almost ten years with Roche. The company announced that his departure will become effective at the end of July 2026.
Moore’s retirement prompted Roche to implement a broader succession plan that includes appointments beyond the chief executive position for its North American diagnostics business.
Leadership changes of this nature resemble other planned executive leadership transitions in which organizations separate board continuity from day-to-day executive management.
In addition to naming Malarek as President and CEO, Roche introduced changes designed to support commercial operations across the United States. These appointments were announced together as part of the company’s leadership transition.
The company also confirmed that the President and CEO position will continue operating from Indianapolis, preserving the existing headquarters location for Roche Diagnostics North America.
Antonio Vergara Assumes New Commercial Leadership Role
Roche announced that Antonio Vergara will become Chief Commercial Officer of Roche Diagnostics U.S., a newly created executive position effective August 1, 2026.
Vergara will report directly to Malarek and oversee the company’s commercial organization together with its U.S. business units.
The new role expands Roche’s executive leadership structure by creating a dedicated position focused on commercial operations in the United States.
Vergara brings approximately three decades of experience with Roche. After joining the company in 1996 as a financial controller, he held leadership positions across finance, commercial operations and general management in multiple regions.
His previous assignments included serving as President and Head of Diagnostics Latin America. Most recently, he led the U.S. Core Lab and Near Patient Care business as Senior Vice President.
The appointment forms part of Roche’s broader organizational changes accompanying the leadership transition in North America. Similar commercial leadership appointments often combine operational oversight with executive succession to support organizational continuity.
Dan Malarek’s Career Across the Roche Group
Leadership Roles Within Roche Diagnostics
Malarek joined the Roche Group in 2007 through the Perspectives Management Development Program.
During his career within Roche Diagnostics, he held several leadership positions covering marketing, business development and general management.
His responsibilities included serving as Head of Marketing and Business Development in Diabetes Care, Lifecycle Leader in Molecular Diagnostics and General Manager of Roche Diagnostics Norway.
Malarek later became Global Head of Marketing and Customer Insights for Roche Diagnostics before moving to Foundation Medicine.
These assignments provided leadership experience across commercial, operational and international business functions within the Roche organization.
Transition From Foundation Medicine
Before accepting his new position, Malarek served as Chief Executive Officer of Foundation Medicine Inc., an independent affiliate of the Roche Group.
His appointment to lead Roche Diagnostics North America creates a leadership vacancy at Foundation Medicine, resulting in an interim executive appointment while the company searches for a permanent successor.
The transition also reconnects Malarek with Roche Diagnostics after leading Foundation Medicine.
Foundation Medicine Announces Interim Chief Executive
Vera Grossmann Appointed Interim CEO
Roche confirmed that Vera Grossmann will become interim Chief Executive Officer of Foundation Medicine effective August 1, 2026.
Grossmann currently serves as Chief Operating Officer at Foundation Medicine and will assume interim leadership immediately following Malarek’s transition to Roche Diagnostics North America.
The interim appointment is intended to provide executive continuity during the company’s search for a permanent chief executive.
Frequently Asked Questions
Who is Dan Malarek?
Dan Malarek is the incoming President and CEO of Roche Diagnostics North America. Before the appointment, he served as Chief Executive Officer of Foundation Medicine Inc.
When does Dan Malarek become CEO of Roche Diagnostics North America?
Malarek assumes the position on August 1, 2026.
Who is retiring from Roche Diagnostics North America?
Brad Moore will retire at the end of July 2026 after nearly ten years with Roche.
What is Antonio Vergara’s new role at Roche?
Antonio Vergara has been appointed Chief Commercial Officer of Roche Diagnostics U.S., a newly created executive position responsible for leading the company’s U.S. commercial organization and business units.
Who will lead Foundation Medicine after Dan Malarek’s appointment?
Foundation Medicine Chief Operating Officer Vera Grossmann will serve as interim Chief Executive Officer while the company conducts a search for a permanent successor.
